{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:32:45Z","timestamp":1792373565545,"version":"4.4.0"},"reference-count":308,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000199","name":"U.S. Department of Agriculture","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000199","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.583077","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T04:10:02Z","timestamp":1601439002000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":312,"title":["Emerging Concepts and Technologies in Vaccine Development"],"prefix":"10.3389","volume":"11","author":[{"given":"Morgan","family":"Brisse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia M.","family":"Vrba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinh","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.10.004","article-title":"Immunologic basis of vaccine vectors","volume":"33","author":"Liu","year":"2010","journal-title":"Immunity"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1400472111","article-title":"History of vaccination","volume":"111","author":"Plotkin","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.01963","article-title":"New vaccine technologies to combat outbreaksituations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/302490a0","article-title":"Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen","volume":"302","author":"Smith","year":"1983","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/311067a0","article-title":"Live recombinant vaccinia virus protects chimpanzees against hepatitis B","volume":"311","author":"Moss","year":"1984","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.67.4.2370-2375.1993","article-title":"Protection of cats against feline leukemia virus by vaccination witha canarypox virus recombinant, ALVAC-FL","volume":"67","author":"Tartaglia","year":"1993","journal-title":"J Virol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1995.1430","article-title":"Herpesvirus of turkey recombinant viruses expressing infectious bursal disease virus (IBDV) VP2 immunogen induce protection against an IBDV virulent challenge in chickens","volume":"211","author":"Darteil","year":"1995","journal-title":"Virology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1017\/s0950268800052535","article-title":"The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; A link between Jenner and Pasteur","volume":"116","author":"Pastoret","year":"1996","journal-title":"Epidemiol Infect"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.74.14.6358-6367.2000","article-title":"Vaccination against Canine Distemper Virus Infection in Infant Ferrets with and without Maternal Antibody Protection, Using Recombinant Attenuated Poxvirus Vaccines","volume":"74","author":"Welter","year":"2000","journal-title":"J Virol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.jcpa.2007.04.015","article-title":"Immunization of Puppies in the Presence of Maternally Derived Antibodies Against Canine Distemper Virus","volume":"137","author":"Pardo","year":"2007","journal-title":"J Comp Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.09.068","article-title":"Three-year duration of immunity in cats vaccinated with a canarypox-vectored recombinant rabies virus vaccine","volume":"30","author":"Jas","year":"2012","journal-title":"Vaccine"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1637\/10540-032613-Reg.1","article-title":"Protection and antibody response caused by turkey herpesvirus vector newcastle disease vaccine","volume":"57","author":"Esaki","year":"2013","journal-title":"Avian Dis"},{"key":"B13","unstructured":"First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response | FDA"},{"key":"B14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as vaccine vectors for infectious diseases and cancer","volume":"8","author":"Draper","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02705-15","article-title":"A Novel Live Pichinde Virus-Based Vaccine Vector Induces Enhanced Humoral and Cellular Immunity after a Booster Dose","volume":"90","author":"Dhanwani","year":"2015","journal-title":"J Virol"},{"key":"B16","article-title":"Recombinant Tri-Segmented Pichinde Virus as a Novel Live Viral Vaccine Platform","volume-title":"Methods in molecular biology","author":"Dhanwani","year":"2017"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.79.16.10200-10209.2005","article-title":"Replicating Rather than Nonreplicating Adenovirus-HumanImmunodeficiency Virus Recombinant Vaccines Are Better at Eliciting Potent Cellular Immunity andPriming High-Titer Antibodies","volume":"79","author":"Peng","year":"2017","journal-title":"J Virol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.04.060","article-title":"Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains","volume":"34","author":"Condit","year":"2016","journal-title":"Vaccine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2005.09.020","article-title":"Replication-defective viruses as vaccines and vaccine vectors","volume":"344","author":"Dudek","year":"2006","journal-title":"Virology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1419067","article-title":"Single-cycle adenovirus vectors in the current vaccine landscape","volume":"17","author":"Barry","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4103\/0974-777X.77299","article-title":"Fundamentals of vaccine immunology","volume":"3","author":"Clem","year":"2011","journal-title":"J GlobalInfect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response tovaccination","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.vaccine.2012.10.083","article-title":"Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development","volume":"31","author":"Kushnir","year":"2012","journal-title":"Vaccine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus\u2013like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.06.028","article-title":"Recombinant HIV-1 Pr55gag virus-like particles: Potent stimulators of innate and acquired immune responses","volume":"42","author":"Deml","year":"2005","journal-title":"Mol Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1089\/088922200309368","article-title":"Priming of strong, broad, and long-lived HIV type 1 p55(gag)-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques","volume":"16","author":"Paliard","year":"2000","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1131929100","article-title":"Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection","volume":"100","author":"Murata","year":"2003","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1159\/000150482","article-title":"Virus-like Particles Induce MHC Class I-Restricted T-Cell Responses: Lessons learned from the hepatitis B small surface antigen","volume":"39","author":"Schirmbeck","year":"1996","journal-title":"Intervirology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2010.161","article-title":"Cross-presentation of epitopes on virus-like particles via the MHC i receptor recycling pathway","volume":"89","author":"Win","year":"2011","journal-title":"Immunol Cell Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2006.07.018","article-title":"Virus-like particles: Passport to immune recognition","volume":"40","author":"Grgacic","year":"2006","journal-title":"Methods"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.6.3.381","article-title":"Virus-like particles: Flexible platforms for vaccine development","volume":"6","author":"Chackerian","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"B32","unstructured":"ENGERIX-B [Hepatitis B Vaccine (Recombinant)] injectable suspension, for intramuscular use"},{"key":"B33","unstructured":"Cervarix, Suspension for Intramuscular Injection"},{"key":"B34","unstructured":"Hepatitis B Vaccine (Recombinant) Suspension for intramuscular injection"},{"key":"B35","unstructured":"GARDASIL\u00ae [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] Suspension for intramuscular injection"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208394","article-title":"A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants","volume":"367","author":"Agnandji","year":"2012","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children","volume":"365","author":"Agnandji","year":"2011","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014538","article-title":"Influenza virus-like particles containing M2 induce broadly crossprotective immunity","volume":"6","author":"Song","year":"2011","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.03.043","article-title":"Comparison of the efficacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease","volume":"27","author":"El-Attar","year":"2009","journal-title":"Vaccine"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1743-422X-8-3","article-title":"Prime immunization with rotavirus VLP 2\/6 followed by boosting withan adenovirus expressing VP6 induces protective immunization against rotavirus inmice","volume":"8","author":"Zhou","year":"2011","journal-title":"Virol J"},{"key":"B41","article-title":"Subunit protein vaccine delivery system for tuberculosis based on hepatitis B virus core VLP (HBc-VLP) particles","volume-title":"Methods in Molecular Biology","author":"Dhanasooraj","year":"2016"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005608","article-title":"Zika virus-like particle (VLP) based vaccine","volume":"11","author":"Boigard","year":"2017","journal-title":"PloS Negl Trop Dis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/QAI.0b013e31820b844e","article-title":"CD40L-containing virus-like particle as a candidate HIV-1 vaccine targeting dendritic cells","volume":"56","author":"Franco","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-8518-8-7","article-title":"HIV-1 sub-type C chimaeric VLPs boost cellular immune responses inmice","volume":"8","author":"Pillay","year":"2010","journal-title":"J Immune Based Ther Vaccines"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2016.03.001","article-title":"Engineering virus-like particles as vaccine platforms","volume":"18","author":"Frietze","year":"2016","journal-title":"Curr Opin Virol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fimmu.2018.02224","article-title":"Nanoparticle vaccines against infectious diseases","volume":"9","author":"Pati","year":"2018","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.11.069","article-title":"Nanoparticle vaccines","volume":"32","author":"Zhao","year":"2014","journal-title":"Vaccine"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/polym10010031","article-title":"Polymer-based nanomaterials and applications for vaccines anddrugs","volume":"10","author":"Han","year":"2018","journal-title":"Polym (Basel)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.7150\/thno.20745","article-title":"Rational design of polymeric hybrid micelles to overcome lymphaticand intracellular delivery barriers in cancer immunotherapy","volume":"7","author":"Li","year":"2017","journal-title":"Theranostics"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00022","article-title":"Nanoparticle-Based Vaccines Against RespiratoryViruses","volume":"10","author":"Al-Halifa","year":"2019","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19113605","article-title":"DNA vaccines\u2014How far from clinical use","volume":"19","author":"Hobernik","year":"2018","journal-title":"Int J Mol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"26","DOI":"10.11599\/germs.2013.1034","article-title":"DNA vaccines: Roles against diseases","volume":"3","author":"Khan","year":"2013","journal-title":"GERMS"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.08.076","article-title":"DNA vaccines in sheep: CTLA-4 mediated targeting and CpG motifs enhance immunogenicity in a DNA prime\/protein boost strategy","volume":"24","author":"Kennedy","year":"2006","journal-title":"Vaccine"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbiotec.2012.08.012","article-title":"The future of human DNA vaccines","volume":"162","author":"Li","year":"2012","journal-title":"J Biotechnol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CVI.00263-17","article-title":"DNA priming increases frequency of T-cell responses to a vesicularstomatitis virus HIV vaccine with specific enhancement of CD8 T-cell responses by interleukin-12plasmid DNA","volume":"24","author":"Li","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13331-1","article-title":"Combined skin and muscle vaccination differentially impact thequality of effector T cell functions: The CUTHIVAC-001 randomized trial","volume":"7","author":"Haidari","year":"2017","journal-title":"SciRep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00594","article-title":"Advances in mRNA vaccines for infectious diseases","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"FSO300","DOI":"10.4155\/fsoa-2017-0151","article-title":"Latest development on RNA-based drugs and vaccines","volume":"4","author":"Lundstrom","year":"2018","journal-title":"Futur Sci OA"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOMATERIALS.2017.09.033","article-title":"Designing immunostimulatory double stranded messenger RNA with maintained translational activity through hybridization with poly A sequences for effective vaccination","volume":"150","author":"Uchida","year":"2018","journal-title":"Biomaterials"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2016-0102","article-title":"Post isolation modification of exosomes for nanomedicine applications","volume":"11","author":"Hood","year":"2016","journal-title":"Nanomedicine"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2014.957684","article-title":"mRNA-based dendritic cell vaccines","volume":"14","author":"Benteyn","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2011.17","article-title":"Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation","volume":"18","author":"Diken","year":"2011","journal-title":"Gene Ther"},{"key":"B63","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2013.07.011","article-title":"Turning Tumors into Vaccines: Co-opting the Innate Immune System","volume":"39","author":"Van den Boorn","year":"2013","journal-title":"Immunity"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25626","article-title":"Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment","volume":"9","author":"Elion","year":"2018","journal-title":"Oncotarget"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol Ther"},{"key":"B66","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-1-4939-6481-9_3","article-title":"Self-replicating RNA vaccine delivery to dendriticcells","volume":"1499","author":"D\u00e9moulins","year":"2017","journal-title":"Methods Mol Biol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2018.04.019","article-title":"Self-Amplifying Replicon RNA Delivery to Dendritic Cells by Cationic Lipids","volume":"12","author":"Englezou","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines-a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discovery"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol Ther"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302213","article-title":"Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation","volume":"11","author":"Wang","year":"2004","journal-title":"Gene Ther"},{"key":"B72","doi-asserted-by":"publisher","first-page":"79","DOI":"10.21775\/cimb.022.079","article-title":"DNA Vaccines: Regulatory Considerations and Safety Aspects","volume":"22","author":"Myhr","year":"2017","journal-title":"Curr Issues Mol Biol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-6481-9_1","article-title":"Introduction to RNA vaccines","volume":"1499","author":"Kramps","year":"2017","journal-title":"Methods MolBiol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003001","article-title":"Vaccines: From Empirical Development to RationalDesign","volume":"8","author":"Rueckert","year":"2012","journal-title":"PloS Pathog"},{"key":"B75","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1021\/cb300487u","article-title":"Rational epitope design for protein targeting","volume":"8","author":"Peri","year":"2013","journal-title":"ACS Chem Biol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxx077","article-title":"Toward rational antibody design: Recent advancements in molecular dynamics simulations","volume":"30","author":"Yamashita","year":"2018","journal-title":"Int Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/J.COVIRO.2015.03.013","article-title":"Computational tools for epitope vaccine design and evaluation","volume":"11","author":"He","year":"2015","journal-title":"Curr Opin Virol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1084\/JEM.20151960","article-title":"Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design","volume":"213","author":"Rappuoli","year":"2016","journal-title":"J Exp Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Sci (80 )"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Sci (80)"},{"key":"B81","first-page":"73","article-title":"Structural features of broadly neutralizing antibodies and rational design of vaccine","volume-title":"Advances in Experimental Medicine and Biology","author":"Zhou","year":"2018"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.2174\/15680266113136660187","article-title":"Structural Vaccinology: A Three-dimensional View for Vaccine Development","volume":"13","author":"Ferlenghi","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01194","article-title":"Mapping Determinants of Virus Neutralization and Viral Escape forRational Design of a Hepatitis C Virus Vaccine","volume":"9","author":"Keck","year":"2018","journal-title":"Front Immunol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"eaaz6225","DOI":"10.1126\/sciadv.aaz6225","article-title":"Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines","volume":"6","author":"He","year":"2020","journal-title":"Sci Adv"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2016.01.021","article-title":"Evolution of rational vaccine designs for genital herpes immunotherapy","volume":"17","author":"Kaufmann","year":"2016","journal-title":"Curr Opin Virol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04859-5","article-title":"Rational Zika vaccine design via the modulation of antigen membraneanchors in chimpanzee adenoviral vectors","volume":"9","author":"L\u00f3pez-Camacho","year":"2018","journal-title":"Nat Commun"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02187-18","article-title":"Rational Design of Zika Virus Subunit Vaccine with EnhancedEfficacy","volume":"93","author":"Tai","year":"2019","journal-title":"J Virol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07199-6","article-title":"Rational design of a triple-type human papillomavirus vaccine bycompromising viral-type specificity","volume":"9","author":"Li","year":"2018","journal-title":"Nat Commun"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01382","article-title":"Identification of new features from known bacterial protectivevaccine antigens enhances rational vaccine design","volume":"8","author":"Ong","year":"2017","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-1-4939-7104-6_4","article-title":"Rational design to T lymphocyte epitope-based vaccines against Coccidioides infection","volume":"1625","author":"Hurtgen","year":"2017","journal-title":"Methods Mol Biol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1039\/c6cs00858e","article-title":"Principles of mucin structure: Implications for the rational design of cancer vaccines derived from MUC1-glycopeptides","volume":"46","author":"Mart\u00ednez-S\u00e1ez","year":"2017","journal-title":"Chem Soc Rev"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2016.05.001","article-title":"Vaccine technologies: From whole organisms to rationally designed protein assemblies","volume":"120","author":"Karch","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.05.014","article-title":"Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming","volume":"258","author":"Zupan\u010di\u010d","year":"2017","journal-title":"J Control Release"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.7b00958","article-title":"Rational-Differential Design of Highly Specific Glycomimetic Ligands: Targeting DC-SIGN and Excluding Langerin Recognition","volume":"13","author":"Porkolab","year":"2018","journal-title":"ACS Chem Biol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1094595","article-title":"Recombinant and epitope-based vaccines on the road to the market and implications for vaccine design and production","volume":"12","author":"Oyarz\u00fan","year":"2016","journal-title":"Hum Vaccines Immunother"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/156241","article-title":"Structural and Computational Biology in the Design of ImmunogenicVaccine Antigens","volume":"2015","author":"Liljeroos","year":"2015","journal-title":"J Immunol Res"},{"key":"B97","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nri.2017.54","article-title":"Unique aspects of the perinatal immune system","volume":"17","author":"Zhang","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.10.014","article-title":"Innate Immune Function by Toll-like Receptors: Distinct Responses in Newborns and the Elderly","volume":"37","author":"Kollmann","year":"2012","journal-title":"Immunity"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02247","article-title":"Immunosenescence and its hallmarks: How to oppose aging strategically? A review of potential options for therapeutic intervention","volume":"10","author":"Aiello","year":"2019","journal-title":"Front Immunol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10522-014-9514-3","article-title":"Innate immunesenescence: underlying mechanisms and clinical relevance","volume":"16","author":"Hazeldine","year":"2015","journal-title":"Biogerontology"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.5mr0315-104r","article-title":"Paradoxical changes in innate immunity in aging: recent progress and new directions","volume":"98","author":"Montgomery","year":"2015","journal-title":"J Leukoc Biol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2012.04.005","article-title":"Changes in primary lymphoid organs with aging","volume":"24","author":"Chinn","year":"2012","journal-title":"Semin Immunol"},{"key":"B103","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.162.6.3342","article-title":"B cell maintenance in aged mice reflects both increased B cell longevity and decreased B cell generation","volume":"162","author":"Kline","year":"1999","journal-title":"J Immunol"},{"key":"B104","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.158.4.1598","article-title":"Development of B cells in aged mice: decline in the ability of pro-Bcells to respond to IL-7 but not to other growth factors","volume":"158","author":"Stephan","year":"1997","journal-title":"J Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/srep30842","article-title":"The aged lymphoid tissue environment fails to support naive T cellhomeostasis","volume":"6","author":"Becklund","year":"2016","journal-title":"Sci Rep"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2599","article-title":"The origins of age-related proinflammatory state","volume":"105","author":"Ferrucci","year":"2005","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2005.02.055","article-title":"Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity","volume":"579","author":"De Martinis","year":"2005","journal-title":"FEBS Lett"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2002.01381.x","article-title":"Influence of ageing on Langerhans cell migration in mice: Identification of a putative deficiency of epidermal interleukin-1\u03b1","volume":"105","author":"Cumberbatch","year":"2002","journal-title":"Immunology"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0809542","article-title":"Leukocyte function in the aging immune system","volume":"87","author":"Desai","year":"2010","journal-title":"J Leukoc Biol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2008.03658.x","article-title":"Ageing is associated with diminished apoptotic cell clearance in vivo","volume":"152","author":"Aprahamian","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.0105-2896.2005.00276.x","article-title":"Immunosenescence: a problem of lymphopoiesis, homeostasis, microenvironment, and signaling. John Cambier","volume":"205","author":"Cambier","year":"2005","journal-title":"Immunol Rev"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301721","article-title":"Aging and Cytomegalovirus Infection Differentially and Jointly Affect Distinct Circulating T Cell Subsets in Humans","volume":"192","author":"Wertheimer","year":"2014","journal-title":"J Immunol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2012.04.004","article-title":"B cell maintenance and function in aging","volume":"24","author":"Kogut","year":"2012","journal-title":"Semin Immunol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v95.10.3162","article-title":"Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10","volume":"95","author":"Rea","year":"2000","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.imlet.2004.04.015","article-title":"Regulatory T cells and tolerogenic dendritic cells: From basic biology to clinical applications","volume":"94","author":"Rutella","year":"2004","journal-title":"Immunol Lett"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0802046","article-title":"Prednisolone Treatment Induces Tolerogenic Dendritic Cells and a Regulatory Milieu in Myasthenia Gravis Patients","volume":"183","author":"Luther","year":"2009","journal-title":"J Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0801155","article-title":"TLR Triggering on Tolerogenic Dendritic Cells Results in TLR2 Up-Regulation and a Reduced Proinflammatory Immune Program","volume":"183","author":"Chamorro","year":"2009","journal-title":"J Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines3020320","article-title":"Vaccine Adjuvants: from 1920 to 2015 and Beyond","volume":"3","author":"Pasquale","year":"2015","journal-title":"Vaccines"},{"key":"B120","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1172\/JCI81083","article-title":"Beyond antigens and adjuvants: Formulating futurevaccines","volume":"126","author":"Moyer","year":"2016","journal-title":"J Clin Invest"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00103-0","article-title":"Early transcription and silencing of cytokine genes underlie polarization of T helper cell subsets","volume":"14","author":"Grogan","year":"2001","journal-title":"Immunity"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.6.2.133","article-title":"New hepatitis B vaccine formulated with an improved adjuvant system","volume":"6","author":"Kundi","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"B124","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1365-3083.2008.02225.x","article-title":"IC31 \u00ae , a Two-Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice","volume":"69","author":"Olafsdottir","year":"2009","journal-title":"Scand J Immunol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep19570","article-title":"Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens","volume":"6","author":"Knudsen","year":"2016","journal-title":"Sci Rep"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir769","article-title":"GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults","volume":"205","author":"Behzad","year":"2012","journal-title":"J Infect Dis"},{"key":"B127","doi-asserted-by":"publisher","first-page":"e3116","DOI":"10.1371\/journal.pone.0003116","article-title":"Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements","volume":"3","author":"Agger","year":"2008","journal-title":"PloS One"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-017-0020-x","article-title":"DMAb inoculation of synthetic cross reactive antibodies protectsagainst lethal influenza A and B infections","volume":"2","author":"Elliott","year":"2017","journal-title":"NPJ Vaccines"},{"key":"B129","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.imlet.2012.01.003","article-title":"Selective binding of anti-DNA antibodies to native dsDNA fragmentsof differing sequence","volume":"143","author":"Uccellini","year":"2012","journal-title":"Immunol Lett"},{"key":"B130","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.163.11.6306","article-title":"Anti-Double-Stranded DNA Antibodies and Immunostimulatory Plasmid DNA in Combination Mimic the Endogenous IFN-\u03b1 Inducer in Systemic Lupus Erythematosus","volume":"163","author":"Vallin","year":"1999","journal-title":"J Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0500132102","article-title":"The evolution of human anti-double-stranded DNAautoantibodies","volume":"102","author":"Wellmann","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant System AS03 containing \u03b1-tocopherol modulates innate immune response and leads to improved adaptive immunity","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccine"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2010.03.027","article-title":"Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response","volume":"145","author":"Henriksen-Lacey","year":"2010","journal-title":"J Control Release"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.10.036","article-title":"A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human","volume":"32","author":"van Dissel","year":"2014","journal-title":"Vaccine"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.6.5.723","article-title":"GlaxoSmithKline Adjuvant Systems in vaccines: Concepts, achievements and perspectives","volume":"6","author":"Gar\u00e7on","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807381","article-title":"Efficacy of RTS,S\/AS01E vaccine against malaria in children 5 to 17 months of age","volume":"359","author":"Bejon","year":"2008","journal-title":"N Engl J Med"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70262-0","article-title":"Efficacy of RTS,S\/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: A randomised controlled trial","volume":"11","author":"Olotu","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.pervac.2011.05.006","article-title":"Vaccines of the future","volume":"1","author":"Stanberry","year":"2011","journal-title":"Perspect Vaccinol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00978.x","article-title":"Use of defined TLR ligands as adjuvants within humanvaccines","volume":"239","author":"Duthie","year":"2011","journal-title":"Immunol Rev"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e3181eaca65","article-title":"Toll-like receptor agonists are they good adjuvants","volume":"16","author":"Gnjatic","year":"2010","journal-title":"Cancer J"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901296","article-title":"TLR-Activated Dendritic Cells Enhance the Response of Aged Naive CD4 T Cells via an IL-6\u2013Dependent Mechanism","volume":"185","author":"Jones","year":"2010","journal-title":"J Immunol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1086\/428589","article-title":"Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with respiratory syncytial virus and other viral respiratory infections","volume":"191","author":"Gill","year":"2005","journal-title":"J Infect Dis"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03193-13","article-title":"Defective Interfering Influenza Virus RNAs: Time To Reevaluate Their Clinical Potential as Broad-Spectrum Antivirals","volume":"88","author":"Dimmock","year":"2014","journal-title":"J Virol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00743-08","article-title":"Influenza Virus Protecting RNA: an Effective Prophylactic and Therapeutic Antiviral","volume":"82","author":"Dimmock","year":"2008","journal-title":"J Virol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0166-0934(02)00260-4","article-title":"Defective influenza A virus generated entirely from plasmids: Its RNA is expressed in infected mouse lung and modulates disease","volume":"108","author":"Duhaut","year":"2003","journal-title":"J Virol Methods"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-8-212","article-title":"Defective interfering virus protects elderly mice from influenza","volume":"8","author":"Scott","year":"2011","journal-title":"Virol J"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049394","article-title":"Cloned Defective Interfering Influenza Virus Protects Ferrets from Pandemic 2009 Influenza A Virus and Allows Protective Immunity to Be Established","volume":"7","author":"Dimmock","year":"2012","journal-title":"PloS One"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2012.09.017","article-title":"Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir","volume":"96","author":"Dimmock","year":"2012","journal-title":"Antiviral Res"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.06.114","article-title":"Defective interfering influenza virus confers only short-lived protection against influenza virus disease: Evidence for a role for adaptive immunity in DI virus-mediated protection in vivo","volume":"29","author":"Scott","year":"2011","journal-title":"Vaccine"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.034132-0","article-title":"Defective interfering influenza A virus protects in vivo against disease caused by a heterologous influenza B virus","volume":"92","author":"Scott","year":"2011","journal-title":"J Gen Virol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.01.102","article-title":"A novel broad-spectrum treatment for respiratory virus infections: Influenza-based defective interfering virus provides protection against pneumovirus infection in vivo","volume":"29","author":"Easton","year":"2011","journal-title":"Vaccine"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.01852","article-title":"The antiviral and antitumor effects of defective interfering particles\/genomes and their mechanisms","volume":"10","author":"Yang","year":"2019","journal-title":"Front Microbiol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1212785","article-title":"Biologics to treat substance use disorders: Current status and new directions","volume":"12","author":"Pravetoni","year":"2016","journal-title":"Hum Vaccines Immunother"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/378727a0","article-title":"Suppression of psychoactive effects of cocaine by active immunization","volume":"378","author":"Carrera","year":"1995","journal-title":"Nature"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.5b00085","article-title":"Efficacy, but Not Antibody Titer or Affinity, of a Heroin Hapten Conjugate Vaccine Correlates with Increasing Hapten Densities on Tetanus Toxoid, but Not on CRM197 Carriers","volume":"26","author":"Jalah","year":"2015","journal-title":"Bioconjug Chem"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2015.02.030","article-title":"Molecular attributes of conjugate antigen influence function of antibodies induced by anti-nicotine vaccine in mice and non-human primates","volume":"25","author":"McCluskie","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1021\/acschembio.6b00977","article-title":"An advance in prescription opioid vaccines: Overdose mortality reduction and extraordinary alteration of drug half-life","volume":"12","author":"Kimishima","year":"2017","journal-title":"ACS Chem Biol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201511654","article-title":"Combatting Synthetic Designer Opioids: A Conjugate Vaccine Ablates Lethal Doses of Fentanyl Class Drugs","volume":"55","author":"Bremer","year":"2016","journal-title":"Angew Chemie Int Ed"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00084","article-title":"Methamphetamine Vaccines: Improvement through Hapten Design","volume":"59","author":"Collins","year":"2016","journal-title":"J Med Chem"},{"key":"B160","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1124\/pr.117.013904","article-title":"Conjugate Vaccine Immunotherapy for Substance Use Disorder","volume":"69","author":"Bremer","year":"2017","journal-title":"Pharmacol Rev"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01427","article-title":"A Stable Heroin Analogue That Can Serve as a Vaccine Hapten to Induce Antibodies That Block the Effects of Heroin and Its Metabolites in Rodents and That Cross-React Immunologically with Related Drugs of Abuse","volume":"61","author":"Sulima","year":"2018","journal-title":"J Med Chem"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuropharm.2016.12.005","article-title":"Active vaccination attenuates the psychostimulant effects of \u03b1-PVP and MDPV in rats","volume":"116","author":"Nguyen","year":"2017","journal-title":"Neuropharmacology"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1021\/jo001442w","article-title":"An immunotherapeutic program for the treatment of nicotine addiction: Hapten design and synthesis","volume":"66","author":"Isomura","year":"2001","journal-title":"J Org Chem"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.117150","article-title":"Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse","volume":"322","author":"Peterson","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1021\/ja108807j","article-title":"Impact of distinct chemical structures for the development of a methamphetamine vaccine","volume":"133","author":"Moreno","year":"2011","journal-title":"J Am Chem Soc"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1021\/jm200461m","article-title":"A vaccine strategy that induces protective immunity against heroin","volume":"54","author":"Stowe","year":"2011","journal-title":"J Med Chem"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.189506","article-title":"An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia","volume":"341","author":"Pravetoni","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"B168","doi-asserted-by":"publisher","first-page":"e76557","DOI":"10.1371\/journal.pone.0076557","article-title":"Selection of a Novel Anti-Nicotine Vaccine: Influence of Antigen Design on Antibody Function in Mice","volume":"8","author":"Pryde","year":"2013","journal-title":"PloS One"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1021\/jm3013745","article-title":"Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens","volume":"56","author":"Pravetoni","year":"2013","journal-title":"J Med Chem"},{"key":"B170","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1021\/bc500016k","article-title":"Investigating hapten clustering as a strategy to enhance vaccines against drugs of abuse","volume":"25","author":"Collins","year":"2014","journal-title":"Bioconjug Chem"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2016.03.028","article-title":"Optimization of a methamphetamine conjugate vaccine for antibody production in mice","volume":"35","author":"Stevens","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.7b03334","article-title":"Development of a Clinically Viable Heroin Vaccine","volume":"139","author":"Bremer","year":"2017","journal-title":"J Am Chem Soc"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101807","article-title":"Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats","volume":"9","author":"Pravetoni","year":"2014","journal-title":"PloS One"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00425-X","article-title":"Human therapeutic cocaine vaccine: Safety and immunogenicity","volume":"20","author":"Kosten","year":"2002","journal-title":"Vaccine"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.04.032","article-title":"Vaccine pharmacotherapy for the treatment of cocaine dependence","volume":"58","author":"Martell","year":"2005","journal-title":"Biol Psychiatry"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1021\/mp900213u","article-title":"A critical evaluation of a nicotine vaccine within a self-administration behavioral model","volume":"7","author":"Moreno","year":"2010","journal-title":"Mol Pharm"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.07.038","article-title":"Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food","volume":"31","author":"R\u00fcedi-Bettschen","year":"2013","journal-title":"Vaccine"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082557","article-title":"Immunogenicity of individual vaccine components in a bivalent nicotine vaccine differ according to vaccine formulation and administration conditions","volume":"8","author":"Cornish","year":"2013","journal-title":"PloS One"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.04.003","article-title":"Vaccine for cocaine dependence: A randomized double-blind placebo-controlled efficacy trial","volume":"140","author":"Kosten","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"B180","doi-asserted-by":"publisher","first-page":"e96547","DOI":"10.1371\/journal.pone.0096547","article-title":"Effect of Currently Approved Carriers and Adjuvants on the Pre-Clinical Efficacy of a Conjugate Vaccine against Oxycodone in Mice and Rats","volume":"9","author":"Pravetoni","year":"2014","journal-title":"PloS One"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2015.09.012","article-title":"Anti-nicotine vaccines: Comparison of adjuvanted CRM197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human primates","volume":"29","author":"McCluskie","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1219159110","article-title":"Dynamic vaccine blocks relapse to compulsive intake of heroin","volume":"110","author":"Schlosburg","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002547","article-title":"A vaccine against nicotine for smoking cessation: A randomizedcontrolled trial","volume":"3","author":"Cornuz","year":"2008","journal-title":"PloS One"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.317","article-title":"Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic","volume":"89","author":"Hatsukami","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1586\/erv.13.13","article-title":"Therapeutic vaccines against tobacco addiction","volume":"12","author":"Fahim","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2009.128","article-title":"Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: A randomized, double-blind, placebo-controlled efficacy trial","volume":"66","author":"Martell","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00722-8","article-title":"Preclinical Evaluation of Vaccines to Treat Opioid Use Disorders: How Close are We to a Clinically Viable Therapeutic","volume":"34","author":"Townsend","year":"2020","journal-title":"CNS Drugs"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30190-1","article-title":"Pertussis and influenza immunisation during pregnancy: a landscape review","volume":"17","author":"Raya","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1007\/5584_2019_407","article-title":"New Pertussis Vaccines: A Need and aChallenge","author":"Hozbor","year":"2019","journal-title":"Pertussis Infection and Vaccines (book), New Pertussis Vaccines: A Need and a Challenge (book section)"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1586\/erv.11.60","article-title":"Review of diphtheria, tetanus and pertussis vaccines in clinical development","volume":"10","author":"Kitchin","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.7b00692","article-title":"Toxoid Vaccination against Bacterial Infection Using Cell Membrane-Coated Nanoparticles","volume":"29","author":"Angsantikul","year":"2018","journal-title":"Bioconjug Chem"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx681","article-title":"Preclinical and clinical development of neoantigen vaccines","volume":"28","author":"Li","year":"2017","journal-title":"Ann Oncol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0751-1","article-title":"The perfect personalized cancer therapy: Cancer vaccines against neoantigens","volume":"37","author":"Aurisicchio","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"B194","doi-asserted-by":"publisher","first-page":"654","DOI":"10.12688\/f1000research.18693.1","article-title":"Strategies for developing and optimizing cancervaccines","volume":"8","author":"Maeng","year":"2019","journal-title":"F1000Research"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.4161\/21645515.2014.973317","article-title":"Antigen-specific vaccines for cancer treatment","volume":"10","author":"Tagliamonte","year":"2014","journal-title":"Hum Vaccines Immunother"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Sci (80)"},{"key":"B197","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13046-019-1154-7","article-title":"Cancer DNA vaccines: current preclinical and clinical developmentsand future perspectives","volume":"38","author":"Lopes","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B198","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.3390\/ijms19102890","article-title":"Cancer vaccine immunotherapy with RNA-loadedliposomes","volume":"19","author":"Sayour","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00929.x","article-title":"Induction of anti-tumor immunity with epidermal cells pulsed with tumor- derived RNA or intradermal administration of RNA","volume":"114","author":"Granstein","year":"2000","journal-title":"J Invest Dermatol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200635910","article-title":"Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA","volume":"36","author":"Scheel","year":"2006","journal-title":"Eur J Immunol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2957","article-title":"Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy","volume":"72","author":"Van Lint","year":"2012","journal-title":"Cancer Res"},{"key":"B202","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep22509","article-title":"Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours","volume":"6","author":"Bialkowski","year":"2016","journal-title":"Sci Rep"},{"key":"B203","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40425-015-0068-y","article-title":"Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I\/IIa study","volume":"3","author":"K\u00fcbler","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020989709019","article-title":"In vivo characteristics of cationic liposomes as delivery vectors for gene therapy","volume":"19","author":"Audouy","year":"2002","journal-title":"Pharm Res"},{"key":"B205","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2015.02.003","article-title":"Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics","volume":"203","author":"Lorenzer","year":"2015","journal-title":"J Control Release"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-005-0064-z","article-title":"Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor\/self antigen","volume":"55","author":"Hess","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"B207","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1038\/srep05128","article-title":"Intranasal mRNA nanoparticle vaccination induces prophylactic andtherapeutic anti-tumor immunity","volume":"4","author":"Phua","year":"2014","journal-title":"Sci Rep"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.6b03329","article-title":"Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy","volume":"17","author":"Oberli","year":"2017","journal-title":"Nano Lett"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034833","article-title":"Phase I clinical trial of systemically administeredTUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans","volume":"7","author":"Lu","year":"2012","journal-title":"PloS One"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62166-7","article-title":"Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: A phase 1 first-in-human trial (DISCOVER)","volume":"381","author":"Cho","year":"2013","journal-title":"Lancet"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0541","article-title":"Preclinical mammalian safety studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)","volume":"16","author":"Wagner","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric Antigen Receptor\u2013Modified T Cells in Chronic Lymphoid Leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4356","article-title":"Elimination of large tumors in mice by mRNA-encoded bispecific antibodies","volume":"23","author":"Stadler","year":"2017","journal-title":"Nat Med"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt245","article-title":"A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients","volume":"24","author":"Wilgenhof","year":"2013","journal-title":"Ann Oncol"},{"key":"B215","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/794528","article-title":"RNA-Based Vaccines in Cancer Immunotherapy","volume":"2015","author":"McNamara","year":"2015","journal-title":"J Immunol Res"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1256527","article-title":"Systemic activation of antigen-presenting cells via RNA-Loadednanoparticles","volume":"6","author":"Sayour","year":"2017","journal-title":"Oncoimmunology"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.4121","article-title":"Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patientswith pretreated advanced melanoma","volume":"34","author":"Wilgenhof","year":"2016","journal-title":"J Clin Oncol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.11.009","article-title":"mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma","volume":"26","author":"Wang","year":"2018","journal-title":"Mol Ther"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1177\/0022034518764416","article-title":"Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer","volume":"97","author":"Tan","year":"2018","journal-title":"J Dent Res"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00766","article-title":"Personalized dendritic cell vaccines-recent breakthroughs andencouraging clinical results","volume":"10","author":"Mastelic-Gavillet","year":"2019","journal-title":"Front Immunol"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2013.09.002","article-title":"Challenges and advances towards the rational design of mRNA vaccines","volume":"19","author":"Pollard","year":"2013","journal-title":"Trends Mol Med"},{"key":"B223","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1159\/000082484","article-title":"Rational design of vaccination strategies to promote antigen entryinto the MHC class I-restricted presentation pathway","volume":"77","author":"Becker","year":"2017","journal-title":"Transfus MedHemother"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1364322","article-title":"Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations","volume":"13","author":"Gatti-Mays","year":"2017","journal-title":"Hum Vaccines Immunother"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00008","article-title":"Vaccine strategies to improve anticancer cellular immuneresponses","volume":"10","author":"Vermaelen","year":"2019","journal-title":"Front Immunol"},{"key":"B226","doi-asserted-by":"publisher","first-page":"5408","DOI":"10.1038\/s41467-019-13368-y","article-title":"Engineering dendritic cell vaccines to improve cancerimmunotherapy","volume":"10","author":"Perez","year":"2019","journal-title":"Nat Commun"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1455505","article-title":"Virus-like antigen display for cancer vaccine development, what is the potential","volume":"17","author":"Sander","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2018-0147","article-title":"Nanoparticle systems for cancer vaccine","volume":"8","author":"Wen","year":"2019","journal-title":"Nanomedicine"},{"key":"B229","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","article-title":"Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial","volume":"15","author":"Butts","year":"2014","journal-title":"Lancet Oncol"},{"key":"B230","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.biomaterials.2014.10.053","article-title":"CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses","volume":"40","author":"Rosalia","year":"2015","journal-title":"Biomaterials"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou348","article-title":"multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: The ACT III study","volume":"17","author":"Schuster","year":"2015","journal-title":"Neuro Oncol"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.08.062","article-title":"Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer","volume":"33","author":"Riabov","year":"2015","journal-title":"Vaccine"},{"key":"B233","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejca.2020.03.018","article-title":"Efficacy and safety of the therapeutic cancervaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized,neoadjuvant phase-II study (ABCSG-34)","volume":"132","author":"Singer","year":"2020","journal-title":"Eur J Cancer"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0283","article-title":"Efficient eradication of established tumors in mice with cationic liposome-based synthetic long-peptide vaccines","volume":"5","author":"Varypataki","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2017.12.011","article-title":"Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer","volume":"14","author":"Zupan\u010di\u010d","year":"2018","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2016.0268","article-title":"Tumour virus vaccines: Hepatitis B virus and humanpapillomavirus","volume":"372","author":"Stanley","year":"2017","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0335","article-title":"A single vaccination with polyomavirus VP1\/VP2Her2 virus-like particles prevents outgrowth of HER-2\/neu-expressing tumors","volume":"65","author":"Tegerstedt","year":"2005","journal-title":"Cancer Res"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-007-0281-8","article-title":"Dendritic cells loaded with polyomavirus VP1\/VP2Her2 virus-like particles efficiently prevent outgrowth of a Her2\/neu expressing tumor","volume":"56","author":"Tegerstedt","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23920","article-title":"Murine pneumotropic virus chimeric Her2\/ neu virus-like particles as prophylactic and therapeutic vaccines against Her2\/ neu expressing tumors","volume":"124","author":"Andreasson","year":"2009","journal-title":"Int J Cancer"},{"key":"B240","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.nano.2011.09.010","article-title":"Induction of tumor-specific immunity by multi-epitope rat HER2\/neu-derived peptides encapsulated in LPD Nanoparticles","volume":"8","author":"Jalali","year":"2012","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1171446","article-title":"Proof of concept study with an HER-2 mimotope anticancer vaccinededuced from a novel AAV-mimotope library platform","volume":"5","author":"Singer","year":"2016","journal-title":"Oncoimmunology"},{"key":"B242","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.biomaterials.2016.12.030","article-title":"Plant viral nanoparticles-based HER2 vaccine: Immune response influenced by differential transport, localization and cellular interactions of particulate carriers","volume":"121","author":"Shukla","year":"2017","journal-title":"Biomaterials"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-017-8969-0","article-title":"Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8+ T response","volume":"66","author":"Arab","year":"2018","journal-title":"Immunol Res"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1408749","article-title":"Virus-like particle display of HER2 induces potent anti-cancerresponses","volume":"7","author":"Palladini","year":"2018","journal-title":"Oncoimmunology"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0666-9","article-title":"A virosomal formulated Her-2\/neu multi-peptide vaccine induces Her-2\/neu-specific immune responses in patients with metastatic breast cancer: A phase i study","volume":"119","author":"Wiedermann","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0088","article-title":"Immunotherapy with a HER2-Targeting listeria induces HER2-Specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma","volume":"22","author":"Mason","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B247","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nnano.2015.292","article-title":"In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer","volume":"11","author":"Lizotte","year":"2016","journal-title":"Nat Nanotechnol"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2018.09.004","article-title":"Protein-based nanoparticles in cancer vaccine development","volume":"15","author":"Neek","year":"2019","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"B249","volume-title":"List of Blueprint priority diseases","year":"2018"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609462","article-title":"Efficacy of a Low-Cost, Heat-Stable Oral Rotavirus Vaccine in Niger","volume":"376","author":"Isanaka","year":"2017","journal-title":"N Engl J Med"},{"key":"B251","unstructured":""},{"key":"B252","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/biot.201800376","article-title":"Emerging Technologies for Low-Cost, Rapid VaccineManufacture","volume":"14","author":"Kis","year":"2019","journal-title":"Biotechnol J"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1016\/J.VACCINE.2016.03.085","article-title":"Universal influenza vaccines: Shifting to better vaccines","volume":"34","author":"Berlanda Scorza","year":"2016","journal-title":"Vaccine"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1016\/J.VACCINE.2017.04.085","article-title":"Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology","volume":"35","author":"Gilbert","year":"2017","journal-title":"Vaccine"},{"key":"B255","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.coviro.2016.01.007","article-title":"Selection of HIV vaccine candidates for concurrent testing in an efficacy trial","volume":"17","author":"Huang","year":"2016","journal-title":"Curr Opin Virol"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1038\/srep20617","article-title":"Chimpanzee adenovirus vaccine provides multispecies protectionagainst rift valley fever","volume":"6","author":"Warimwe","year":"2016","journal-title":"Sci Rep"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1306615","article-title":"Vaccines for epidemic infections and the role of CEPI","volume":"13","author":"Plotkin","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1016\/J.VACCINE.2016.10.080","article-title":"Policy making for vaccine use as a driver of vaccine innovation and development in the developed world","volume":"35","author":"Seib","year":"2017","journal-title":"Vaccine"},{"key":"B259","unstructured":"172 countries & multiple candidate vaccines engaged in COVID-19 Vaccine Global Access Facility \u2013 CEPI"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2019.04.013","article-title":"Preventing an Antigenically Disruptive Mutation in Egg-Based H3N2 Seasonal Influenza Vaccines by Mutational Incompatibility","volume":"25","author":"Wu","year":"2019","journal-title":"Cell Host Microbe"},{"key":"B261","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/jama.2018.0345","article-title":"Novel vaccine technologies: Essential Components of an AdequateResponse to Emerging Viral Diseases","volume":"319","author":"Graham","year":"2018","journal-title":"JAMA"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 Vaccines at Pandemic Speed","volume":"382","author":"Lurie","year":"2020","journal-title":"N Engl J Med"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1007\/s40475-020-00201-6","article-title":"The SARS-CoV-2 Vaccine Pipeline: an Overview","volume":"7","author":"Chen","year":"2020","journal-title":"Curr Trop Med Rep"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 Vaccines: Status Report","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity"},{"key":"B265","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/d41586-020-00751-9","article-title":"Don\u2019t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees","volume":"579","author":"Jiang","year":"2020","journal-title":"Nature"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202048663","article-title":"COVID-19 vaccines: knowing the unknown","volume":"50","author":"Lv","year":"2020","journal-title":"EurJ Immunol"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0321-6","article-title":"The potential danger of suboptimal antibody responses in COVID-19","volume":"20","author":"Iwasaki","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31354-4","article-title":"COVID-19 vaccines for all","volume":"395","author":"Usher","year":"2020","journal-title":"Lancet"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30763-7","article-title":"Ensuring global access to COVID-19 vaccines","volume":"395","author":"Yamey","year":"2020","journal-title":"Lancet"},{"key":"B270","unstructured":"Survival of the Most: Why Multiple Vaccines May Be the Best Way to Stop the COVID-19 Pandemic"},{"key":"B271","unstructured":"Multiple vaccines could be needed to fully stop COVID-19 pandemic, UW vaccinologist says - GeekWire"},{"key":"B272","unstructured":"Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) - Full Text View - ClinicalTrials.gov"},{"key":"B273","unstructured":"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults - Full Text View - ClinicalTrials.gov"},{"key":"B274","unstructured":"A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults - Full Text View - ClinicalTrials.gov"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.30.20142570","article-title":"Phase 1\/2 Study to Describe the Safety and Immunogenicity of aCOVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report","author":"Mulligan","year":"2020","journal-title":"medRxiv"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.17.20176651","article-title":"RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study","author":"Walsh","year":"2020","journal-title":"medRxiv Prepr Serv Heal Sci"},{"key":"B277","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase 1\/2 study of COVID-19 RNA vaccine BNT162b1 in adults","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"B278","unstructured":"ISRCTN17072692: Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women"},{"key":"B279","unstructured":"Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects - Full Text View - ClinicalTrials.gov"},{"key":"B280","unstructured":"A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18-59 years and 60 years and above"},{"key":"B281","unstructured":"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers - Full Text View - ClinicalTrials.gov"},{"key":"B282","unstructured":"Reports Positive Interim Phase I Data for COVID-19 DNA Vaccine, Joins \u201cWarp Speed\u201d Primate Study"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.28.225649","article-title":"Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model","author":"Patel","year":"2020","journal-title":"bioRxiv"},{"key":"B284","unstructured":"Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults - Full Text View - ClinicalTrials.gov"},{"key":"B285","unstructured":"Study of COVID-19 DNA Vaccine (AG0301-COVID19) - Full Text View - ClinicalTrials.gov"},{"key":"B286","unstructured":"Study of COVID-19 DNA Vaccine (AG0302-COVID19) - Full Text View - ClinicalTrials.gov"},{"key":"B287","volume-title":"A prospective, randomized, adaptive, phase I\/II clinical study to evaluate the safety andimmunogenicity of Novel Corona Virus -2019-nCov vaccine candidate of M\/s Cadila Healthcare Limitedby intradermal route in healthy subjects","year":""},{"key":"B288","unstructured":"Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19 - Full Text View - ClinicalTrials.gov"},{"key":"B289","unstructured":"Immunity and Safety of Covid-19 Synthetic Minigene Vaccine - Full Text View - ClinicalTrials.gov"},{"key":"B290","unstructured":"Safety and Immunity of Covid-19 aAPC Vaccine - Full Text View - ClinicalTrials.gov"},{"key":"B291","unstructured":"Phase Ib-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults - Full Text View - ClinicalTrials.gov"},{"key":"B292","unstructured":"Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With\/Without Matrix-M Adjuvant - Full Text View - ClinicalTrials.gov"},{"key":"B293","unstructured":"SCB-2019 as COVID-19 Vaccine - Full Text View - ClinicalTrials.gov"},{"key":"B294","unstructured":"Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection - Full Text View - ClinicalTrials.gov"},{"key":"B295","unstructured":"A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 - Full Text View - ClinicalTrials.gov"},{"key":"B296","unstructured":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine - Full Text View - ClinicalTrials.gov"},{"key":"B297","unstructured":"An interventional study to evaluate the safety and immune response of a vaccine against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2, the virus that causes COVID-19 infection) when given to healthy adult participants"},{"key":"B298","unstructured":"A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults - Full Text View - ClinicalTrials.gov"},{"key":"B299","unstructured":"Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years. - Full Text View - ClinicalTrials.gov"},{"key":"B300","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"B301","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"key":"B302","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirustype-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-humantrial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"B303","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"B304","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3096","article-title":"Covid-19: Where are we on immunity and vaccines","volume":"370","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"B305","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"B306","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3205","article-title":"Covid-19: Russia approves vaccine without large scale testing or published results","volume":"370","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"B307","unstructured":"Clinical Trial to Evaluate the Safety and Immunogenicitiy of the COVID-19 Vaccine - Full Text View - ClinicalTrials.gov"},{"key":"B308","unstructured":"A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001) - Full Text View - ClinicalTrials.gov"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.583077\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T14:44:51Z","timestamp":1696776291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.583077\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":308,"alternative-id":["10.3389\/fimmu.2020.583077"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.583077","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,30]]},"article-number":"583077"}}